Official Title: A SINGLE-CENTER, NON-RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, TWO-TREATMENT STUDY INVESTIGATING THE ABSOLUTE ORAL
Balovaptan Archives - CmaxInsight
Official Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults Wi
Roche Template
PDF) 5.13 Effects of Balovaptan on Health-Related Quality of Life of Adult Men With ASD: Results From a Phase 2 Randomized Double-Blind Placebo Controlled Study (Vanilla)
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Autismus-Forschung: Roche erhält Breakthrough-Status für Balovaptan
Balovaptan and Autism Spectrum Disorder
Bust for Balovaptan in Treatment of Childhood Autism | MedPage Today
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial - The Lancet Psychiatry
FDA accelerează aprobarea balovaptan, primul tratament pentru principalele simptome ale autismului
Roche culls key phase 3 drug trials, including a cancer med and an autism 'breakthrough' therapy | Fierce Biotech
Swiss drugmaker wins FDA's breakthrough therapy label for autism drug
T. Willgoss- Effects of Balovaptan on Health-Related Quality of Life of Adult Males with Autism - YouTube
Innovator's Corner | PharmaVoice
A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder | Science Translational Medicine
Date 2008
Treatments targeting social behavior hormone show promise with autism
Ready or not, two drugs for autism edge closer to clinic | Spectrum | Autism Research News
Upcoming events – Roche aims to change autism and Ocular awaits pivotal results | Evaluate
New Drugs May Influence Social Behaviors in Those With Autism - Consumer Health News | HealthDay
Roche wins FDA's breakthrough therapy label for autism drug | Reuters
Experimental autism drug balovaptan granted Breakthrough Therapy Designation - Neuro Central
